|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
Charles Lin | Yung-Shun Wen | Yung-Shun Wen | 04-24637115 | 5F., No.32, Keya Rd., Daya Dist.Taichung City, Taiwan (R.O.C.) | 2024/01/24 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | We focus on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and major depressive disorder. These chronic diseases not only cause long-term burdens to the patients and their families but also consume huge social costs. Long-acting release product is a solution to improve medical quality, enhance patient’s compliance, and increase drug adherence. The unique long-acting release platform developed by Alar is different from the current long-acting technologies. Drug products developed by our platform have distinctive characteristics such as low viscosity, small injection volume, and smooth drug release profile with fewer side effects, which provide a better medical choice for patients. We believe that with the corporate philosophy of improving medical quality, it will reach the milestones of excellence in developing long-acting drug products. |
Market Information ( 2024/05/17 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
1697.301 | 285.50 | 258.50 | 280.00 | 19.50 | 1862 | .00 | N/A | N/A | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/05/17) |
TPEx measures adopted (2024/05/17) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | Y | N | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |